Form 4: Arcellx Director David Lubner Reports Ownership Changes

Arcellx, Inc. Director David Lubner has reported changes in beneficial ownership of company stock and stock options following a merger with Gilead Sciences, Inc.

Summary

• David Charles Lubner, a Director at Arcellx, Inc., has filed a Form 4 detailing transactions related to the company's acquisition by Gilead Sciences, Inc.
• The filing indicates that on April 28, 2026, Lubner's common stock holdings were directly owned, with no securities acquired or disposed of in this specific transaction.
• Several stock options, with exercise prices ranging from $6.28 to $63.68, were canceled and converted into the right to receive cash payments and Contingent Value Rights (CVRs).
• Each CVR represents the right to receive a contingent payment of $5.00 in cash per CVR.
• The merger agreement stipulated that tendered shares were exchanged for $115.00 per share in cash, plus one CVR per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, as it confirms the successful completion of a merger with a significant cash payout and potential for additional value through CVRs for shareholders and option holders.

Positives

• The merger with Gilead Sciences, Inc. provides a significant cash payout of $115.00 per share for common stock tendered.
• Holders of stock options are entitled to cash payments for the intrinsic value of their options (Closing Amount minus exercise price) and CVRs.
• The inclusion of Contingent Value Rights (CVRs) offers potential for additional future payments of $5.00 per CVR.

Negatives

• All outstanding stock options were canceled as part of the merger, although converted into cash and CVRs.
• The cash payment for stock options is subject to the exercise price being less than the Closing Amount ($115.00).

Risks

• The value of the CVRs is contingent and dependent on future events or milestones, the specifics of which are not detailed in this filing.
• Withholding taxes will be applied to cash payments received from the merger and option conversions.

Future Outlook

The future outlook for Arcellx is now tied to its integration with Gilead Sciences, Inc. and the potential realization of value from the Contingent Value Rights (CVRs).

Management Comments

• Each outstanding option was canceled and converted into the right to receive a lump-sum cash payment equal to the excess of the Closing Amount over the exercise price, plus one CVR for each share subject to the option.
• Shares of common stock tendered were exchanged for $115.00 per share in cash, plus one CVR.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the completion of a significant M&A event, where a larger pharmaceutical company (Gilead Sciences) acquires a smaller biotech firm (Arcellx), a common strategy for pipeline expansion and technology acquisition in the biopharmaceutical industry.

Comparison to Industry Standards

• The acquisition terms, including a cash component and a contingent value right, are not uncommon in the biotechnology sector, particularly for companies with promising but not yet fully commercialized assets.
• The $115.00 per share cash offer represents a substantial premium, typical for strategic acquisitions aimed at securing innovative drug candidates or platforms.

Stakeholder Impact

• Shareholders: Receive $115.00 cash per share plus one CVR, representing a significant return on investment.
• Option Holders: Receive cash for the intrinsic value of their options and one CVR per share underlying the option.
• Employees: May be impacted by integration plans and potential changes in employment status following the acquisition.

Next Steps

• Shareholders and option holders will receive cash payments and CVRs as per the merger agreement.
• The realization of CVR value will depend on the terms and conditions outlined in the contingent value rights agreement.

Key Dates

Recommendation

This filing confirms the completion of a merger with a substantial cash component and CVRs. For existing shareholders and option holders, the immediate financial outcome is clear. However, the future value of the CVRs is uncertain and depends on specific milestones. Therefore, a 'hold' recommendation is appropriate as the immediate transaction is complete, and further action depends on the CVR realization.

Keywords

Arcellx, ACLX, Form 4, David Lubner, Gilead Sciences, Merger, Stock Options, Contingent Value Rights, Beneficial Ownership, SEC Filing